Gynecologic Cancers

Gynecologic cancer is diagnosed every six minutes in America. Though nearly 1 in 20 women are affected by this cancer, there are more promising treatments today than ever before. Beaumont offers innovative diagnostic and treatment options, a multidisciplinary approach, and a focus on patients' clinical and emotional needs.

As knowledge about gynecologic cancer continues to expand, more encouraging treatment options are available now than ever before. At Beaumont Hospitals, our highly skilled physicians and excellent oncology staff are on the leading edge of research, diagnosis and individualized intervention.

Board-certified gynecologic oncologists, nurse clinicians and a dedicated staff make up Beaumont's Gynecologic Oncology Division. With innovative diagnostic and treatment options, participation in clinical trials, a multidisciplinary approach and a focus on each of our patient's clinical and emotional needs, the gynecological team delivers the coordination and continuity of care that supports treatment.

Beaumont Gynecologic Oncology Division patients benefit from the collaboration of multidisciplinary teams that meet weekly to review individual patient cases and discuss treatment plans.

Beaumont's expertise is further demonstrated through the use of minimally invasive laparoscopic procedures for gynecological cancer. This approach significantly shortens recovery times (two weeks rather than up to six weeks), lessens postoperative pain, requires smaller incisions and reduces the risk of complications. Recent research has shown that less invasive procedures may also yield additional outcome benefits over a laparotomy (which requires a larger abdominal incision).

Additionally, benefits of minimally invasive surgery for endometrial and cervical cancer are limited to shorter hospitalization and shorter recovery. Other possible benefits are fewer transfusions and wound complications.

Types of gynecologic cancer

The most common and serious gynecologic cancers occur in the ovaries, endometrium (lining of the uterus), cervix, vulva, and vagina. Although these sites of origin are often considered as a single group, each has significant differences in etiology(the cause or origin of a disease as determined by medical diagnosis), prevention, detection, and treatment.

The division is a member of the Southwest Oncology Group and the Gynecologic Oncology Group, and participates in numerous clinical trials related to treatment of gynecologic cancer. These trials give patients access to research protocols in nearly every type of gynecologic cancer